Webinar description:
Are you an academic group in Scotland developing an advanced therapy or vaccine? On behalf of and in collaboration with Scottish Enterprise, Cell and Gene Therapy Catapult's commercialisation experts are holding a new round of fully funded workshops where successful applicants will get one to one access to technical and clinical experts within their field. The initial in-person workshop, and follow on support of up to four online calls over a 12-month period, will aid the development of a bespoke target product profile (TPP) and action plan to optimise chances of successful technology development.
A TPP is a directional tool that needs to be developed from an early stage of a medicinal product’s development; it captures aspirational product attributes to steer the evidence generation plan, address regulatory and reimbursement requirements, aid development of strategies that reduce downstream risks and ultimately increase the probability of successful therapy adoption. This opportunity will also cover the QTPP which is a prospective summary of the quality characteristics of a drug product to ensure the desired quality, taking into account safety and efficacy. Both the TPP and QTPP are dynamic, living documents that are updated as evidence is generated during development.
This webinar will cover:
- The first-hand experiences from a successful applicant of the 2024 call for the workshop
- The importance of a TPP for early-stage development
- What we are offering to support academics in Scotland developing advanced therapies and vaccines
- Who is eligible and how to apply for this opportunity.
Who should watch?
Academic groups in Scotland developing advanced therapies or vaccines are encouraged to attend.